Institutional Investors Show Renewed Interest in Immix Biopharma SBI Securities Co. Ltd. recently acquired 17,500 shares of Immix Biopharma, valued at $38,000. The move reflects growing institutional interest, with 11.26% of the company now owned by such investors. The company’s stock has seen fluctuations, with a one-year range between $1.26 and $3.35, and analysts forecasting potential growth.3